A BILL 
To authorize the Patient-Centered Outcomes Research Trust 
Fund to fund research of the symptoms of COVID– 
19, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘COVID–19 Long 
4
Haulers Act’’. 
5
23:14 Jun 15, 2021
H2754
2 
•HR 2754 IH
SEC. 2. AUTHORIZATION TO FUND RESEARCH OF THE 
1
LONG-TERM SYMPTOMS OF COVID–19 BY THE 
2
PATIENT-CENTERED OUTCOMES RESEARCH 
3
TRUST FUND. 
4
(a) IN GENERAL.—The Patient-Centered Outcomes 
5
Research Trust Fund under section 1181 of the Social Se-
6
curity Act (42 U.S.C. 1320e(b)) shall fund research de-
7
scribed in subsection (b). 
8
(b) RESEARCH DESCRIBED.—For purposes of sub-
9
section (a), research described in this subsection shall in-
10
clude— 
11
(1) prior to creating a patient registry described 
12
in paragraph (2), survey existing patient registries 
13
that include individuals experiencing post-acute 
14
sequelae of COVID–19 (in this section, referred to 
15
as ‘‘PASC’’); 
16
(2) creating a patient registry for those with 
17
COVID–19 with information that— 
18
(A) contains the— 
19
(i) symptoms that arise while an indi-
20
vidual is initially infected with COVID–19 
21
and that resolve over time; 
22
(ii) symptoms that arise while an indi-
23
vidual is initially infected with COVID–19 
24
and that extend beyond the resolution of 
25
initial symptoms; 
26
23:14 Jun 15, 2021
H2754
3 
•HR 2754 IH
(iii) symptoms that arise after an in-
1
dividual is initially infected with COVID– 
2
19 and that endure and that the clinician 
3
of such individual has reason to suspect 
4
were related to the COVID–19 diagnosis; 
5
(iv) symptoms that arise in an indi-
6
vidual that may be related to COVID–19 
7
but a diagnosis of COVID–19 was not ob-
8
tained and cannot be identified due to a 
9
lack of antibodies, false negative test re-
10
sults, or lack of access to timely testing; 
11
(v) treatments of individuals after pri-
12
mary diagnosis to COVID–19 and the ef-
13
fectiveness 
of 
such 
treatments 
14
disaggregated by age, gender, race or eth-
15
nicity, and co-morbidities and related post- 
16
viral illnesses overlapping with PASC; and 
17
(vi) any other relevant questions or 
18
issues related to individuals who experience 
19
a diagnosis of, treatment for, and manage-
20
ment of care with COVID–19, PASC, or 
21
related post-viral illnesses overlapping with 
22
PASC; and 
23
(B) synthesizes information relating to in-
24
dividuals experiencing post-acute sequelae of 
25
23:14 Jun 15, 2021
H2754
4 
•HR 2754 IH
COVID–19 identified from the survey described 
1
in paragraph (1) and information under the pa-
2
tient registry described in paragraph (2); and 
3
(3) outreach and inclusion (as appropriate) in-
4
dividuals from communities with PASC, traditional 
5
health 3 disparities and inequities and related post- 
6
viral illnesses overlapping with PASC. 
7
(c) REPORT.—Not later than 1 year after the estab-
8
lishment of the synthesized patient registry described in 
9
subsection (a)(2), and annually thereafter, the Patient- 
10
Centered Outcomes Research Institute shall submit data, 
11
findings, and information with respect to the status of the 
12
patient registry (including progress, barriers, and issues) 
13
to Congress and the President. 
14
(d) AUTHORIZATION OF APPROPRIATIONS.—There is 
15
hereby authorized $30,000,000 for fiscal year 2022 to 
16
carry out this section, which shall remain available until 
17
expended. 
18
SEC. 3. RESEARCH ON UNITED STATES HEALTH CARE SYS-
19
TEM’S RESPONSE TO LONG-TERM SYMPTOMS 
20
OF COVID–19. 
21
(a) IN GENERAL.—The Secretary of Health and 
22
Human Services, acting through the Director of the Agen-
23
cy for Healthcare Research and Quality, shall conduct or 
24
support research related to the United States health care 
25
23:14 Jun 15, 2021
H2754
5 
•HR 2754 IH
system’s response to long-term symptoms of COVID–19, 
1
including with respect to— 
2
(1) the expansion and efficacy of post-infectious 
3
disease treatment, including— 
4
(A) identifying obstacles to access for vet-
5
erans, the elderly, disabled, and low-income 
6
communities; 
7
(B) evaluating and identifying potential 
8
gaps or other weaknesses that bear on gender, 
9
geographic, racial and ethnic disparities on 
10
COVID–19 infection rates, severity and length 
11
of symptoms, and outcomes; 
12
(C) identifying gaps in compliance with 
13
health care privacy and security rules; and 
14
(D) evaluating whether diagnosis, access 
15
to, or treatment associated with medical pro-
16
viders and care delivered in different settings 
17
varied by gender, disability, geographic, racial 
18
and ethnic group; and 
19
(2) conducting and support rapid turnaround 
20
research to— 
21
(A) identify health care strategies that 
22
help mitigate gender, geographic, disability, ra-
23
cial and ethnic disparities in COVID–19 infec-
24
23:14 Jun 15, 2021
H2754
6 
•HR 2754 IH
tion rates, severity and length of symptoms, 
1
secondary illnesses, and outcomes; 
2
(B) identify health care-related factors 
3
contributing to such disparities in COVID–19 
4
infection rates, hospitalizations, severity and 
5
length of disease, secondary illnesses, and out-
6
comes; and 
7
(C) provide recommendations on ensuring 
8
equity in diagnosis and access to quality post- 
9
infectious treatments that may be advanced to 
10
mitigate such disparities, going forward. 
11
(b) PROTOCOLS
ON PASC PATIENTS.—The Sec-
12
retary of Health and Human Services, acting through the 
13
Director of the Agency for Healthcare Research and Qual-
14
ity, shall coordinate cross-agency engagement with leaders 
15
from communities with PASC, traditional health dispari-
16
ties and inequities and related post-viral illnesses overlap-
17
ping with PASC— 
18
(1) to develop protocols that ensure PASC pa-
19
tients have access to medical professionals educated 
20
about post-infectious disease and treatments; and 
21
(2) to provide guidance on PASC diagnostics, 
22
treatments, and care that takes into account gender, 
23
geographic, racial and ethnic disparities. 
24
23:14 Jun 15, 2021
H2754
7 
•HR 2754 IH
(c) AUTHORIZATION OF APPROPRIATIONS.—There is 
1
authorized to be appropriated to carry out this section 
2
$30,000,000 for fiscal year 2022 to carry out this section, 
3
which shall remain available until expended. 
4
SEC. 4. EDUCATION AND DISSEMINATION OF INFORMATION 
5
WITH RESPECT TO LONG-TERM SYMPTOMS 
6
OF COVID–19. 
7
(a) POST-ACUTE SEQUELAE OF COVID–19 (PASC) 
8
PUBLIC EDUCATION PROGRAM.—The Secretary of Health 
9
and Human Services, acting through the Director of the 
10
Centers for Disease Control and Prevention, shall develop 
11
and disseminate to the public information regarding 
12
PASC, including information on— 
13
(1) the awareness, incidence, and common 
14
symptoms of PASC among COVID–19 patients; 
15
(2) illnesses related and often comorbid with 
16
PASC, including but not limited to, 
17
(A) myalgic encephalomyelitis/chronic fa-
18
tigue syndrome (ME/CFS) and fibromyalgia 
19
(FM); 
20
(B) postural orthostatic tachycardia syn-
21
drome 
(POTS) 
and 
other 
forms 
of 
22
dysautonomia; 
23
(C) autoimmune diseases associated with 
24
viral triggers; 
25
23:14 Jun 15, 2021
H2754
8 
•HR 2754 IH
(D) connective tissue diseases exacerbated 
1
or triggered by infections; and 
2
(E) mast cell activation syndrome (MCAS); 
3
and 
4
(3) the availability, as medically appropriate, of 
5
treatment options for PASC and related post-viral 
6
illnesses overlapping with PASC, as identified in sec-
7
tion (2) above. 
8
(b) POST-ACUTE SEQUELAE OF COVID–19 (PASC) 
9
PROVIDER
EDUCATION
PROGRAM.—The Secretary of 
10
Health and Human Services, acting through the Director 
11
of the Centers for Disease Control and Prevention, shall 
12
in consultation with communities with PASC, traditional 
13
health disparities and inequities and related post-viral ill-
14
nesses overlapping with PASC, develop and disseminate 
15
to health care providers information on PASC for the pur-
16
pose of ensuring that health care providers remain in-
17
formed about current information on this emerging illness 
18
and related post-infectious illnesses, which have been 
19
shown to be closely related to PASC including information 
20
on— 
21
(1) myalgic encephalomyelitis/chronic fatigue 
22
syndrome (ME/CFS) and fibromyalgia (FM); 
23
(2) postural orthostatic tachycardia syndrome 
24
(POTS) and other forms of dysautonomia; 
25
23:14 Jun 15, 2021
H2754
9 
•HR 2754 IH
(3) autoimmune diseases associated with viral 
1
triggers; 
2
(4) connective tissue diseases exacerbated or 
3
triggered by infections; and 
4
(5) mast cell activation syndrome (MCAS). 
5
(c) DISSEMINATION
OF INFORMATION.—The Sec-
6
retary may disseminate information under subsection (a) 
7
and subsection (b) directly or through arrangements with 
8
intra-agency initiatives, nonprofit organizations, consumer 
9
groups, institutions of higher learning (as defined in sec-
10
tion 101 of the Higher Education Act of 1965 (20 U.S.C. 
11
1001)), or Federal, State, or local public private partner-
12
ships. 
13
(d) AUTHORIZATION OF APPROPRIATIONS.—There is 
14
authorized to be appropriated to carry out this section 
15
$30,000,000 for fiscal year 2022 to carry out this section, 
16
which shall remain available until expended. 
17
SEC. 5. RESEARCH WITH RESPECT TO MEDICAID COV-
18
ERAGE OF LONG-TERM SYMPTOMS OF COVID– 
19
19. 
20
(a) RESEARCH.—The Administrator of the Centers 
21
for Medicare & Medicaid Services (referred to in this sec-
22
tion as the ‘‘Administrator’’) shall expand the Chronic 
23
Conditions Data Warehouse research database of such 
24
Centers for Medicare and Medicaid Services to collect data 
25
23:14 Jun 15, 2021
H2754
10 
•HR 2754 IH
on items and services furnished to individuals experiencing 
1
post-acute sequelae of COVID–19 under a State plan (or 
2
a waiver of such a plan) under the Medicaid program 
3
under title XIX of the Social Security Act (42 U.S.C. 
4
1396 et seq.) or under a State child Health plan (or a 
5
waiver of such a plan) under the Children’s Health Insur-
6
ance Program under title XXI of such Act (42 U.S.C. 
7
1397aa et seq.) for the treatment of post-acute sequelae 
8
of COVID–19 for purposes of assessing the frequency at 
9
which COVID–19 survivors are furnished such items and 
10
services. 
11
(b) AUTHORIZATION OF APPROPRIATIONS.—There is 
12
authorized to be appropriated to carry out this section 
13
$3,000,000 for fiscal years 2022 to carry out this section, 
14
which shall remain available until expended. 
15
Æ 
23:14 Jun 15, 2021
H2754
